On 20 September 2026, CONCH MAT TECH (02560.HK) said a court froze 39m domestic shares, 6.73%, held by major shareholder Linyi Haihong until 17 September 2029.
On 18 September 2026, YUNFENG FIN (00376.HK) will sell Yunfeng Financial Markets to Yu Feng's Mega Investment for HKD 8,054,998, a connected transaction.
On 18 September 2026, JINGXIN (002020.SZ) filed for a Main Board listing on HKEX, with CITIC Securities as sole sponsor; 2025 revenue was RMB 4,069.4 million.
The HSI fell 0.22% while the HSTECH rose 1.97%; southbound net inflow hit HKD 12.01 billion. XIZHI TECH-P rose 22.61%, HQVT led weekly gains.
HK recently listed stocks diverged this week, with HQVT leading gains at 95.59% and Century Group International leading losses at 86.15%. Z.AI ranked first in liquidity with average daily turnover of approximately HK$8.30 billion. QIYUNSHAN FOOD led in deviation from issue price at 743.12%, while REFIRE recorded the deepest break below issue price at 94.45%. Next week, three recently listed stocks — NSING TECH, FS.COM and NEW VISION CO — will see lock-up expiries, totalling 32,372,800 shares.
On 18 September 2026, SHENYANG PUBLIC (00747.HK) announced the disposal of 100% equity interest in the target company, Shenzhen Jusheng Chuangjian Investment Development Co., Ltd., to Shenzhen Chengb Castle Century Trading Co., Ltd. at a consideration of RMB 2,000,000, with the purchaser wholly owned by Zhang Zehao.
This week's Going Global Weekly with mainland enterprises' Hong Kong listings and pharma globalisation forming the two main lines. On the financing side, TRANSSION, RED AVENUE NEW MATERIALS, ROBOTECHNIK and Junxin Environmental Protection passed the Hong Kong Stock Exchange listing hearing, CCTECH and SKYCHEM TECHNOLOGY advanced their H-share plans, Nazhen Technology launched its global offering with net fundraising of up to approximately HK$6.296 billion, and FORMS SYNTRON announced a delayed listing with refunds; on the pharma side, GENFLEET-B, LEADS BIOLABS-B and CSPC PHARMA released clinical data at WCLC, IMPACT THERAP-B received a positive opinion from CHMP, and GENSCRIPT BIO reached a wet laboratory services cooperation with the Lilly TuneLab platform.
On 18 September 2026, TRANSTHERA-B (02617.HK) announced that its self-developed Jeentai® (tinengotinib) has been included in the CSCO Guidelines for the Diagnosis and Treatment of Biliary Tract Malignancies as a Class II recommendation, category 2A, for advanced biliary tract malignancies.
On 18 September 2026, IMPACT THERAP-B (07630.HK) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending approval of sepalna (Sepalna®) for the maintenance treatment of advanced epithelial ovarian, fallopian tube and primary peritoneal cancer, with the application to be submitted to the European Commission for a final decision.
On 18 September 2026, CISI FIN (06058.HK) announced that its indirectly wholly-owned subsidiary CISI Investment disposed of notes with an aggregate principal amount of USD 20,150,000 in the open market between 15 June and 17 September 2026 at a total consideration of approximately USD 20,080,767.
On 18 September 2026, S HARBOURHOLD (01663.HK) announced that its chairman and substantial shareholder Wang Linbing acquired a total of 3,890,000 ordinary shares in the open market at an average price of approximately HKD 0.056 per share.
On September 18, 2026, the three major Hong Kong stock indices rebounded collectively, with the Hang Seng Index up 0.60%, the Hang Seng TECH Index surging 2.20%, and the Hang Seng China Enterprises Index up 0.61%. The Hang Seng Index's full-day total market turnover was 266.5 billion HKD. On the board, among Stock Connect constituent stocks, XIZHI TECH-P soared 22.61%, with some optical communications concept stocks moving higher.
On September 18, 2026, the three major Hong Kong indices rebounded collectively, with the Hang Seng Index up 0.60%, the Hang Seng TECH Index surging 2.20%, and the Hang Seng China Enterprises Index up 0.61%. The Hang Seng Index's full-day total market turnover was 266.5 billion HKD, Southbound funds saw a net inflow of 1.193 billion HKD.
On 18 September 2026, LIAONING PORT (02880.HK) announced that its wholly-owned subsidiary DBR will acquire the container ship "Jifa Beihai" from Dalian Port Wantong Logistics for RMB 81,613,572.00, a connected transaction.
On 18 September 2026, Shenzhen Transsion Holdings Co., Ltd. (688036.SH) announced that the Listing Committee of HKEX held a listing hearing on 17 September 2026 to consider its application for the issue of overseas-listed foreign shares (H shares) and listing on the Main Board of HKEX, and that its sponsor received a letter from HKEX on 18 September 2026 stating that the Listing Committee has reviewed its listing application.
On 18 September 2026, SHANDONG XINHUA (00719.HK) disclosed that it recently obtained the drug registration certificate for levocarnitine oral solution issued by the National Medical Products Administration.
